Navigation Links
Pharmacyclics Announces Promising Results From Phase 2 Clinical,Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung,Cancer

- Data Support Rationale for Comprehensive Ongoing Phase 2 Program as Combination Agent with Standard Chemotherapies and Pivotal Lung Cancer Trial Scheduled to Begin Early Next Year -

CHICAGO and SUNNYVALE, Calif. June 01, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced promising preliminary results from an open-label Phase 2 clinical trial of Xcytrin(R) (motexafin gadolinium) Injection, the company's lead cancer therapeutic candidate, as a second-line treatment for patients with recurrent, metastatic non-small cell lung cancer (NSCLC) who failed at least one platinum-based chemotherapy regimen. The results were published in the proceedings of the 2007 American Society of Clinical Oncology Annual Meeting (ASCO) taking place this week in Chicago.

"These results indicate that Xcytrin is an active, well-tolerated drug for treatment of recurrent NSCLC," said Richard A. Miller, M.D., president and CEO of Pharmacyclics. "The response rate and survival observed in this trial are comparable to currently approved second-line therapies for NSCLC and support our strategy to conduct multiple ongoing Phase 2 studies of Xcytrin in combination with standard therapies and move into a pivotal trial for this indication early next year. In addition, we are continuing to pursue our new drug application for Xcytrin to treat patients with brain metastases from NSCLC. We believe Xcytrin's selectivity, novel mechanism of action, magnetic resonance imaging detectability, and non-overlapping toxicity with other agents make it an appealing drug to study in combination with other therapies for a broad range of cancers."

The abstract, "A phase II trial of motexafin gadolinium (MGd) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-based chemotherapy: Preliminary results of Stage 1," described interim results from a Phase 2 trial evaluating the safety, tumor response and duratio
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:5/16/2008)...ting that TYKERB and trastuzumab together resulted...on-free survival (PFS), -- Combining TYKERB and t...f the HER2 receptor may create a more complete HER...ERB alone despite patients,previous treatment wit... LONDON and PHILADELPHIA, May 16 /PRNewswire-USNew...
(Date:5/16/2008)...er Novel Approach to Blood ...swire-FirstCall/ -- Pharmacopeia (Nasdaq:,PCOP), a...vel small,molecule therapeutics, announced today t...tor Antagonist (DARA), showed statistically signif...y in patients with mild to,moderate hypertension. ...
(Date:5/15/2008)... Patients with breast or,colorectal cancer, two of...er treatment advances with Avastin(R) (bevacizumab...a that is being presented at the 44th,American Soc... Chicago at,the end of May. Around 30,000 medical ...er event for cancer therapy worldwide., The Roche...
(Date:5/15/2008)...table Tolerability Profile, with Low I...AKE, N.J., May 15 /- The investigatio...9) demonstrated activity in a,heavily pretreated p...atic,breast cancer, according to results of a mult...uggests that eribulin mesylate has a manageable,to...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3ACRIN Study Endorses Virtual Colonoscopy Validation for Colon CAD Software Maker Medicsight plc 440 1ACRIN Study Endorses Virtual Colonoscopy Validation for Colon CAD Software Maker Medicsight plc 440 2ACRIN Study Endorses Virtual Colonoscopy Validation for Colon CAD Software Maker Medicsight plc 440 3ACRIN Study Endorses Virtual Colonoscopy Validation for Colon CAD Software Maker Medicsight plc 440 4Naturally occurring apple compounds reduce risk of pancreatic cancer 668 1Naturally occurring apple compounds reduce risk of pancreatic cancer 668 2Type of ICU Influences Lung Injury Survival 2811 1Type of ICU Influences Lung Injury Survival 2811 2Study Finds Benefits With Drug Coated Stents 2808 1Study Finds Benefits With Drug Coated Stents 2808 2Study Finds Benefits With Drug Coated Stents 2808 3
...BUSINESS WIRE)--Jun 20, 2007 - Array BioPharma,Inc...ta on its MEK,inhibitor, ARRY-162, and its p38 inh...the Annual European Congress of Rheumatology,(EULA...ssociation,of Inflammation Societies, (IAIS) 8th W...rk., ARRY-162 / MEK Inhibitor Phase 1 Results , Ar...
...chusetts --- June,20, 2007 --- Millipore Corporati...ing its ReNcell neural stem cell lines. The,resea...at,University College London and ReNeuron Group pl...pore was announced in 2006. ,The data will be pres...ientist for Millipore’s Bioprocess Division,...
Other Medicine Technology:Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs 2Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs 3Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs 4Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron 2Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron 3Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron 4
(Date:5/16/2008)...asize the Importance of Oral and Overall Health, ...ental insurer United,Concordia Dental is celebrati...ral Health America and the British Dental Health F... to overall health. Beginning May 18,this year,s ...rst time,making it the largest independent intern...
(Date:5/16/2008)...d at the American Society of Clinical Oncology mee...ment practice in about 25 percent of patients with...s to the way colorectal cancers will be staged. ,...e (NCI) SEER population-based statistic registries...ata, shows that outcomes of patients with positive...
(Date:5/16/2008)...sufferers gain benefit from calcitriol, an oral fo...- Taking activated vitamin D may cut the risk of d...dney disease by about one quarter, a new study sug...1,400 patients, those being treated with calcitrio...overall risk of death lowered by 26 percent when c...
(Date:5/16/2008)...t beneath the lining of the uterus (submucosal) ar...ter uterine artery embolization (UAE) but usually ... study. , The study included 49 patients with 1...e and after UAE. The study found that 39 of these ...ometrial cavity after UAE, said Sachit Verma, MD, ...
Breaking Medicine News(10 mins):Health News:United Concordia Dental Celebrates National Smile Month 2Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2
...harles Schumer was very upset and has sent a lette...ration, Dr. Andrew von Eschenbach. In his letter h...he problem.// The confusion started when it was r...d for the patients in case of tissue transplants. ...
...dic Hospital and Beach Resort, located close to Ko...packages for treatment of what is called new-age a...drome (CTS). //The unique health care service wou...eram chief Poly Mathew said Monday: "The hospital ...
... who found a birthmark in her child Matilda found ... internet search to understand the birthmark in he...said her not to panic after a little internet brow...e she contacted Great Ormond Street hospital, Lond...
...n study researchers have seen that people over 60 ... risk of dementia than teetotalers. The Medical Jo...s the lifestyle risk factors for developing dement... research of a sample of 2805 over-60s from Dubbo,...
Other Medicine News:
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: